Arvinas Inc
ARVN7.465USD
+0.045+0.61%
Market hours （ET）Quotes delayed by 15 min
544.95MMarket Cap
LossP/E TTM
More Details of Arvinas Inc Company
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Company Info
Ticker SymbolARVN
Company nameArvinas Inc
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Number of employees430
Security typeOrdinary Share
Fiscal year-endSep 27
Address5 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06511-1966
Phone12035351456
Websitehttps://www.arvinas.com/
Ticker SymbolARVN
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Mr. Briggs W. Morrison, M.D.
Mr. Briggs W. Morrison, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
912.27K
-7.52%
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.86K
-3.34%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
66.81K
+827.20%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
26.05K
+159.93%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
26.05K
+159.93%
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
24.67K
+185.35%
Revenue Breakdown
FY2025Q1
FY2024
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United States
188.80M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.44%
BlackRock Institutional Trust Company, N.A.
6.90%
Citadel Advisors LLC
5.31%
T. Rowe Price Associates, Inc.
5.14%
Pfizer Inc
4.74%
Other
66.47%
Shareholder Types
Shareholders
Proportion
Investment Advisor
36.14%
Hedge Fund
24.67%
Investment Advisor/Hedge Fund
17.48%
Venture Capital
6.80%
Corporation
4.74%
Research Firm
3.41%
Individual Investor
2.23%
Sovereign Wealth Fund
1.70%
Pension Fund
0.37%
Other
2.45%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
503
71.52M
97.99%
-18.05M
2025Q1
525
68.48M
93.89%
-22.67M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
8.35M
11.44%
+1.30M
+18.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.04M
6.9%
-246.30K
-4.66%
Mar 31, 2025
Citadel Advisors LLC
3.88M
5.31%
+395.72K
+11.37%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.75M
5.14%
-273.88K
-6.81%
Mar 31, 2025
Pfizer Inc
3.46M
4.74%
--
--
Mar 31, 2025
RTW Investments L.P.
3.33M
4.57%
--
--
Mar 31, 2025
Logos Global Management LP
3.30M
4.52%
+3.30M
--
Jun 10, 2025
Opaleye Management Inc.
1.98M
2.71%
+350.00K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
1.90M
2.6%
+259.14K
+15.83%
Mar 31, 2025
Alyeska Investment Group, L.P.
1.80M
2.47%
+1.80M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Pharmaceuticals ETF
1.09%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.77%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Tema Oncology ETF
0.41%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares U.S. Pharmaceuticals ETF
0.25%
Zacks Small/Mid Cap ETF
0.18%
JPMorgan Fundamental Data Science Small Core ETF
0.15%
Tema Neuroscience and Mental Health ETF
0.15%
View more
SPDR S&P Pharmaceuticals ETF
Proportion1.09%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.88%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.77%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.46%
Tema Oncology ETF
Proportion0.41%
Federated Hermes MDT Small Cap Core ETF
Proportion0.3%
iShares U.S. Pharmaceuticals ETF
Proportion0.25%
Zacks Small/Mid Cap ETF
Proportion0.18%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.15%
Tema Neuroscience and Mental Health ETF
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
